Your browser doesn't support javascript.
loading
CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language.
Snijders Blok, Lot; Rousseau, Justine; Twist, Joanna; Ehresmann, Sophie; Takaku, Motoki; Venselaar, Hanka; Rodan, Lance H; Nowak, Catherine B; Douglas, Jessica; Swoboda, Kathryn J; Steeves, Marcie A; Sahai, Inderneel; Stumpel, Connie T R M; Stegmann, Alexander P A; Wheeler, Patricia; Willing, Marcia; Fiala, Elise; Kochhar, Aaina; Gibson, William T; Cohen, Ana S A; Agbahovbe, Ruky; Innes, A Micheil; Au, P Y Billie; Rankin, Julia; Anderson, Ilse J; Skinner, Steven A; Louie, Raymond J; Warren, Hannah E; Afenjar, Alexandra; Keren, Boris; Nava, Caroline; Buratti, Julien; Isapof, Arnaud; Rodriguez, Diana; Lewandowski, Raymond; Propst, Jennifer; van Essen, Ton; Choi, Murim; Lee, Sangmoon; Chae, Jong H; Price, Susan; Schnur, Rhonda E; Douglas, Ganka; Wentzensen, Ingrid M; Zweier, Christiane; Reis, André; Bialer, Martin G; Moore, Christine; Koopmans, Marije; Brilstra, Eva H.
Afiliação
  • Snijders Blok L; Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.
  • Rousseau J; Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, 6500AH, The Netherlands.
  • Twist J; Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, 6500HE, The Netherlands.
  • Ehresmann S; CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
  • Takaku M; National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
  • Venselaar H; CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada.
  • Rodan LH; National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
  • Nowak CB; Centre for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.
  • Douglas J; Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
  • Swoboda KJ; Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
  • Steeves MA; Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
  • Sahai I; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Stumpel CTRM; Department of Medical Genetics, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Stegmann APA; Department of Medical Genetics, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Wheeler P; Department of Clinical Genetics and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, 6202AZ, The Netherlands.
  • Willing M; Department of Clinical Genetics and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, 6202AZ, The Netherlands.
  • Fiala E; Nemours Childrens Clinic, Orlando, FL 32827, USA.
  • Kochhar A; Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Gibson WT; Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Cohen ASA; Valley Children's Hospital, Madera, CA 93636, USA.
  • Agbahovbe R; British Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada.
  • Innes AM; Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
  • Au PYB; British Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada.
  • Rankin J; Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
  • Anderson IJ; British Columbia Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada.
  • Skinner SA; Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
  • Louie RJ; Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • Warren HE; Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • Afenjar A; Department of Clinical Genetics, Royal Devon and Exeter NHS Foundation Trust (Heavitree), Exeter, EX2 5DW, UK.
  • Keren B; Division of Genetics, Department of Medicine, University of Tennessee Medical Center, Knoxville, TN 37920, USA.
  • Nava C; Greenwood Genetic Center, Greenwood, SC 29646, USA.
  • Buratti J; Greenwood Genetic Center, Greenwood, SC 29646, USA.
  • Isapof A; Greenwood Genetic Center, Greenwood, SC 29646, USA.
  • Rodriguez D; GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris ; Department of Medical Genetics and Centre de Référence Malformations et maladies congénitales du cervelet et déficiences intellectuelles de causes rares, Armand Trousseau Hospital, GHUEP, AP-HP, Paris, 75012, France.
  • Lewandowski R; AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, 75013, France.
  • Propst J; Groupe de Recherche Clinique (GRC) 'déficience intellectuelle et autisme' UPMC, Paris, 75005, France.
  • van Essen T; AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, 75013, France.
  • Choi M; Groupe de Recherche Clinique (GRC) 'déficience intellectuelle et autisme' UPMC, Paris, 75005, France.
  • Lee S; INSERM, U 1127, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, 75013, Paris, France.
  • Chae JH; AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, 75013, France.
  • Price S; GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris 06; Department Child Neurology and Reference Center for Neuromuscular Diseases "Nord/Est/Ile-de-France", FILNEMUS, Armand Trousseau Hospital, GHUEP, AP-HP, Paris, 75012, France.
  • Schnur RE; GRC ConCer-LD, Sorbonne Universités, UPMC Univ Paris 06; Department of Child Neurology and National Reference Center for Neurogenetic Disorders, Armand Trousseau Hospital, GHUEP, AP-HP, INSERM U1141, 75012, Paris, France.
  • Douglas G; Clinical Genetics Division, Virginia Commonwealth University Health System, Richmond, VA 23298, USA.
  • Wentzensen IM; Clinical Genetics Division, Virginia Commonwealth University Health System, Richmond, VA 23298, USA.
  • Zweier C; Clinical Genetics Department, University Medical Center Groningen, Groningen, 9700RB, The Netherlands.
  • Reis A; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 08826, Republic of Korea.
  • Bialer MG; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 08826, Republic of Korea.
  • Moore C; Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children's Hospital, Seoul, 08826, Republic of Korea.
  • Koopmans M; Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7HE, UK.
  • Brilstra EH; GeneDx, Gaithersburg, MD 20877, USA.
Nat Commun ; 9(1): 4619, 2018 11 05.
Article em En | MEDLINE | ID: mdl-30397230
ABSTRACT
Chromatin remodeling is of crucial importance during brain development. Pathogenic alterations of several chromatin remodeling ATPases have been implicated in neurodevelopmental disorders. We describe an index case with a de novo missense mutation in CHD3, identified during whole genome sequencing of a cohort of children with rare speech disorders. To gain a comprehensive view of features associated with disruption of this gene, we use a genotype-driven approach, collecting and characterizing 35 individuals with de novo CHD3 mutations and overlapping phenotypes. Most mutations cluster within the ATPase/helicase domain of the encoded protein. Modeling their impact on the three-dimensional structure demonstrates disturbance of critical binding and interaction motifs. Experimental assays with six of the identified mutations show that a subset directly affects ATPase activity, and all but one yield alterations in chromatin remodeling. We implicate de novo CHD3 mutations in a syndrome characterized by intellectual disability, macrocephaly, and impaired speech and language.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distúrbios da Fala / Deficiências do Desenvolvimento / DNA Helicases / Mutação de Sentido Incorreto / Complexo Mi-2 de Remodelação de Nucleossomo e Desacetilase / Megalencefalia / Transtornos do Neurodesenvolvimento / Domínios Proteicos / Transtornos da Linguagem Limite: Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distúrbios da Fala / Deficiências do Desenvolvimento / DNA Helicases / Mutação de Sentido Incorreto / Complexo Mi-2 de Remodelação de Nucleossomo e Desacetilase / Megalencefalia / Transtornos do Neurodesenvolvimento / Domínios Proteicos / Transtornos da Linguagem Limite: Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article